Stay updated with breaking news from George Kemble. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN MATEO, Calif., March 25, 2024 -- Sagimet Biosciences Inc. , a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional...
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional
Biotech drug developer Sagimet Biosciences is taking another shot at going public, according to a filing with the SEC late Friday.
Sagimet Biosciences Appoints Life Sciences Industry Veteran Elizabeth Grammer to Board of Directors News provided by Share this article Share this article SAN MATEO, Calif., May 3, 2021 /PRNewswire/ -- Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today the appointment of Elizabeth Grammer, Esq., to its board of directors. Ms. Grammer brings to her role as director over 25 years of experience advising privately held and publicly traded life sciences companies a...
Share this article Share this article SAN MATEO, Calif., March 16, 2021 /PRNewswire/ -- Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH. TVB-2640, is a wholly-owned, oral, selective inhibitor of FASN, a key enzyme involved in the production of saturated fatty acids in the liver and other organs, and is the only enzyme ...